Facts & figures
As of: January, 2019
1) primarily from public funds (EU, Federal Government, State Government); according to Campus Buch: total funding since 1992, incl. BIMSB
2) primarily from own ressources, since 2001
3) primarily from own ressources
4) since 2009
5) since 2006
6) since 2002
| Research Institutions of Campus Berlin-Buch Employees (total) |
2,151 |
|
| of these: | ||
| Max Delbrück Center for Molecular Medicine (MDC): | 1,646 | |
| Leibniz Institute of Molecular Pharmacology (FMP): | 303 | |
| Klinische Forschung Charité Campus Buch: | 202 | |
| Budget and third-party grants (total)1 | EUR 192 million | |
| Max Delbrück Center for Molecular Medicine (MDC): | EUR 147 million | |
| Leibniz Institute of Molecular Pharmacology (FMP): | EUR 29 million | |
| Klinische Forschung Charité Campus Buch: | EUR 16 million | |
| BiotechPark Berlin-Buch | ||
| Number of companies: | 62 | |
| Employees: | 800 | |
| Annual revenue: Percentage of third-party grants: 3,1% |
EUR 220 million |
|
| Hospitals & Patient-Care Institutions | ||
| Employees (total): of these: |
3,564 | |
| HELIOS Klinikum Berlin-Buch: | 2,700 | |
| Evangelische Lungenklinik: | 325 | |
| Immanuel Krankenhaus Berlin, Standort Buch (Rheumaklinik): | 89 |
|
| Patient-care institutions: | 450 | |
| Number of patient beds: | 1,267 | |
| Patients per year (inpatient and outpatient): | 220,519 | |
| Total investment volume of these: |
EUR 1.451 billion | |
| Infrastructure Campus Berlin-Buch1 | EUR 624 million | |
| HELIOS Klinikum Berlin-Buch² | EUR 336 million | |
| Evangelische Lungenklinik3 | EUR 49 million | |
| Immanuel Krankenhaus Berlin, Standort Buch (Rheumaklinik)1 | EUR 39 million |
|
| LudwigPark 3 | EUR 45 million | |
| Allées des Châteaux 3 | EUR 23 million | |
| Widerker Vermögensverwaltung (Schlosspark-Passage) 3 | EUR 29 million |
|
| Ludwig Hoffmann Quartier | EUR 152 million |
|
| Housing construction associations (HOWOGE 3,4, EWG 3,5, WBG 3,6 Hau+S 3,5 ) | EUR 154 million |
News Buch Berlin
Starting up with highly promising immunotherapies
After spending many years researching together, a group of scientists has founded CARTemis Therapeutics, a spin-off from the Max Delbrück Center. Uta Höpken, Armin Rehm, Anthea Wirges, and Mario Bunse...
more ...OMEICOS Therapeutics Provides Update on PMD-OPTION Phase 2a Clinical Study Evaluating OMT-28 in Primary Mitochondrial Disease
OMEICOS, a biopharmaceutical company developing first-in-class small molecule therapeutics based on the profound understanding of omega-3 fatty acid metabolism and physiology, today provided a positiv...
more ...The thrill of science
Young students are fascinated by the experiments they can participate in at the Gläsernes Labor (Life Science Learning Lab). Thanks to a special fundraiser, socially disadvantaged children from the di...
more ...Events Buch Berlin
09.10.2023, 09:00
Explore Precision Medicine Event im Futurium
Das Gläserne Labor beteiligt sich am 9. Oktober 2023 am Explore Precision Medicine Event im Futurium mit Workshops und Präsentationen.
more ...
